HIMS & HERS Health's GLP-1 pill sparks controversy and stock drop

Taylor Goggins reports on HIMS & HERS Health Inc. (HIMS) launching a version of the popular GLP-1 weight loss pill for $49, which initially caused a stock surge but later dropped. Novo Nordisk, the maker of the original Wegovy pill, responded by calling HIMS's pill a "waste" due to its compound's potential inability to be absorbed by the body, intensifying the competition in the weight loss drug market. Jackie DeAngelis questions the long-term commitment required for such pills, noting that weight often returns if medication is stopped.